Inferra AI / Company / IRMD

Iradimed Corp

IRMD · Health Care

Last earnings Oct 30, 2026

Key results

Revenuequarter

$21.2 million

revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

GAAP EPSquarter

$0.43

Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

EPSquarter

$0.47

Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Gross marginquarter

78%

Although we experienced some transitional inefficiencies as we settled into our new Orlando facility early in the quarter, we maintained a strong 78% gross margin.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Three Months Ended September 30, 2025 For the three months ended September 30, 2025, the Company reported revenue of $21.2 million, an increase of $2.9 million, compared to $18.3 million for the comparable period of 2024, an increase of 16%.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Net incomequarter

$5.6 million

The Company reported net income of $5.6 million, compared to $5.0 million for the comparable period of 2024, an increase of 10%, or $0.43 per diluted share, for the three months ended September 30, 2025, compared to $0.40 per diluted share for the same period of 2024, an increase of 8%.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

net income of $6.1 million, which excludes $0.5 million of stock compensation expense, net of tax benefit, compared to $5.5 million, which excludes $0.5 million of stock compensation expense, net of tax benefit, an increase of 10% for the comparable period of 2024.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

On a non-GAAP basis, net income per diluted share was $0.47 for the three months ended September 30, 2025, compared to $0.43 per diluted share for the comparable period of 2024, an increase of 9%.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Revenueytd

$61.1 million

Nine Months Ended September 30, 2025 For the nine months ended September 30, 2025, the Company reported revenue of $61.1 million compared to $53.9 million for the comparable period of 2024, an increase of 13%.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

AI analysis

Q3 2025 · reported Nov 3, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2025

$21.2M

-60.7% -$33M vs year ago computed from stated figures

EX-99 · Nov 3, 2025

GAAP EPS · Q3 2025

$0.43

0.0% vs year ago computed from stated figures

EX-99 · Nov 3, 2025

Gross margin · Q3 2025

78%

EX-99 · Nov 3, 2025

Net income · Q3 2025

$5.6M

+12.0% +$600.00K vs year ago computed from stated figures

EX-99 · Nov 3, 2025

The quarter in charts

Revenue — quarterly

As stated

EX-99 · Nov 3, 2025 Statement values as stated in the release.

Diluted EPS — GAAP

Per diluted share, as stated

EX-99 · Nov 3, 2025 EPS values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

Q3 2025 delivered$21.2M

Guided range (company-stated)$0.0B · midpoint $0.0B

0$B

EX-99 · Nov 3, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

Metric	Q3 2025	Prior qtr	Year ago
Revenue	$21.2 million	$20.4 million	$53.9 million
GAAP EPS	$0.43	$0.45	$0.43
EPS	$0.47	$0.45	—
Gross margin	78%	—	—
Net income	$5.6 million	$5.8 million	$5.0 million

EX-99 · Nov 3, 2025

Guidance · company-stated

Direction: Raised

Revenue$21.2 million

“htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.”

Revenue

“Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.”

Revenue

“We are proud to announce our seventeenth consecutive quarter of record revenue, reaching $21.2 million in the third quarter of 2025 a 16% increase year-over-year and exceeding our previously announced guidance.”

Revenue

“We are raising our guidance for the full-year 2025 revenue to $82.5 million to $83.5 million from the previous revenue of $80.0 million to $82.5 million, GAAP diluted earnings per share to $1.68 to $1.72 from the previous $1.60 to $1.70, and non-GAAP diluted earnings per share to $1.84 to $1.88 from the previous $1.76 to $1.86, added Mr.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Gross margin78%

Capital allocation

Regular Quarterly Cash dividend$0.17

Revenue$21.2M

Dividend$0.17

htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.

What changed vs last quarter

Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.”

Revenue: “Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.”

Revenue: “We are proud to announce our seventeenth consecutive quarter of record revenue, reaching $21.2 million in the third quarter of 2025 a 16% increase year-over-year and exceeding our previously announced guidance.”

Revenue: “We are raising our guidance for the full-year 2025 revenue to $82.5 million to $83.5 million from the previous revenue of $80.0 million to $82.5 million, GAAP diluted earnings per share to $1.68 to $1.72 from the previous $1.60 to $1.70, and non-GAAP diluted earnings per share to $1.84 to $1.88 from the previous $1.76 to $1.86, added Mr.”

Revenue — Raised (“Raises”)
“htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.”

Revenue — Raised (“Raises”)
“Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.”

Revenue — Raised (“increase”)
“We are proud to announce our seventeenth consecutive quarter of record revenue, reaching $21.2 million in the third quarter of 2025 a 16% increase year-over-year and exceeding our previously announced guidance.”

Revenue — Raised (“raising”)
“We are raising our guidance for the full-year 2025 revenue to $82.5 million to $83.5 million from the previous revenue of $80.0 million to $82.5 million, GAAP diluted earnings per share to $1.68 to $1.72 from the previous $1.60 to $1.70, and non-GAAP diluted earnings per share to $1.84 to $1.88 from the previous $1.76 to $1.86, added Mr.”

Classified from the release's primary full-year outlook statement.

Capital allocation

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

We remain committed to operational excellence, innovation, and delivering consistent shareholder returns - including our regular $0.17 quarterly dividend per share, payable on November 25, 2025, said Roger Susi, President and Chief Executive Officer of Iradimed.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

The Company s board of directors declared a regular quarterly cash dividend of $0.17 per share of our outstanding common stock.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

The dividend is payable to stockholders of record as of the close of business on November 14, 2025 and will be paid on November 25, 2025.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements, including statements relating to financial guidance, future quarterly cash dividends, operational issues meeting accelerated demand in the New Facility, commercialization, timing and expected revenue ramping of our next-generation 3870 MRI-compatible IV infusion pump, and the Company s strategic plans, objectives, and intentions.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Strategy & priorities

We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our stockholders through various means.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Risks & headwinds

The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management s current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Risks and uncertainties that may affect the future results of the Company include, but are not limited to: our ability to receive 510(k) clearance for our products and product candidates, complete inspections conducted by the U.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

and global economies, including the impact of increasing and/or fluctuating tax and interest rates as well as inflationary pressures on such economies; geopolitical risks, including tariffs, trade disputes, international conflicts and recent or upcoming elections in the United States and other countries, and the impact of insufficient governmental funding and related operational inefficiencies, which could, among other things, lead to increased volatility in the financial market and in the market in which we operate our business; and other risks detailed in our filings with the United States Securities and Exchange Commission (the SEC ).

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the Company s control that could cause actual results to differ materially from the results discussed in the forward-looking statements.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025

These risks, uncertainties, assumptions and other important factors include, but are not limited to, those included in Part II, Item 1A, Risk Factors of the Company s Quarterly Reports on Form 10-Q, and Part I, Item 1A, Risk Factors of the Company s Annual Report on Form 10-K for the year ended December 31, 2024, as well as those otherwise described or updated from time to time in our other filings with the SEC.

SEC original ↗Iradimed Corp — Earnings release (8-K exhibit)EX-99Nov 3, 2025